{{Refimprove|date=November 2011}}

{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 447812653
| IUPAC_name = 4-(dimethylamino)-2-isopropyl-2-phenylpentanenitrile
| image = isoaminile.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|isoaminile}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 77-51-0
| ATC_prefix = R05
| ATC_suffix = DB04
| PubChem = 6481
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB08944 
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 6236
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = R4823W2PQL
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08088

<!--Chemical data-->
| C=16 | H=24 | N=2 
| molecular_weight = 244.375 g/mol
| smiles = N#CC(c1ccccc1)(C(C)C)CC(N(C)C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H24N2/c1-13(2)16(12-17,11-14(3)18(4)5)15-9-7-6-8-10-15/h6-10,13-14H,11H2,1-5H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = WFLSCFISQHLEED-UHFFFAOYSA-N
}}

'''Isoaminile''' is an [[antitussive]] (cough suppressant) used under the trade-name '''Peracon'''.<ref>{{cite book |author1=Chappel, C. I. |author2=von Seeman, C. |editor1=Ellis, G. P. |editor2=West, G. B. | chapter = Antitussive Drugs | title = Progress in Medicinal Chemistry | year = 1963 | volume = 3 | publisher = Butterworth | isbn = 978-0-444-53322-7  | pages = 114–115 | doi = 10.1016/S0079-6468(08)70117-6 | url = https://books.google.com/books?id=PcyoOmjvGzkC&pg=PA114 | accessdate = 2013-09-12 }}</ref>

The normal therapeutic dose is 40–80&nbsp;mg of the cyclamate salt, with a maximum of five doses in a 24-hour period.{{citation needed|date=January 2013}} In addition to its central antitussive effects, it is also an [[anticholinergic]], exhibiting both [[antimuscarinic]] and [[antinicotinic]] actions.{{citation needed|date=January 2013}}

== References ==
{{Reflist|2}}

{{Cough and cold preparations}}

[[Category:Amines]]
[[Category:Nitriles]]
[[Category:Antitussives]]


{{respiratory-system-drug-stub}}